Bayes analysis supports null hypothesis of anti‐amyloid beta therapy in Alzheimer's disease-Reference-Cited by-同舟云学术

Bayes analysis supports null hypothesis of anti‐amyloid beta therapy in Alzheimer's disease

Published:2021-05-31 Issue:6 Volume:17 Page:1051-1055
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Richard Edo¹²,den Brok Melina G.H.E.¹³,Gool Willem A.²

Affiliation:

1. Department of Neurology, Radboud University Medical Center Donders Institute for Brain, Cognition, and Behaviour Nijmegen the Netherlands

2. Department of Public and Occupational Health Amsterdam University Medical Centre AMC University of Amsterdam the Netherlands

3. Department of Neurology Amsterdam University Medical Centre AMC University of Amsterdam the Netherlands

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Clinical Neurology,Developmental Neuroscience,Health Policy,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/alz.12379

Reference10 articles.

1. Using Bayes factor hypothesis testing in neuroscience to establish evidence of absence

2. Absence of evidence is not evidence of absence;Douglas G;BMJ,1995

3. Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

4. Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

5. A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease;Ostrowitzki S;Alzheimer's Res Ther,2017

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analysis of microisolated frontal cortex excitatory layer III and V pyramidal neurons reveals a neurodegenerative phenotype in individuals with Down syndrome;Acta Neuropathologica;2024-08-06

2. Recalibrating the Risk-Benefit Profiles of Lecanemab and Donanemab: Scales, Immunoreactivity, and Changes in Amyloid-β42;Journal of Alzheimer's Disease;2024-05-28

3. Alzheimer’s disease and its treatment–yesterday, today, and tomorrow;Frontiers in Pharmacology;2024-05-24

4. Investigating Cu(I) binding to model peptides of N-terminal Aβ isoforms;Journal of Inorganic Biochemistry;2024-04

5. Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer’s Disease: A Systematic Review and Network Meta-Analysis;CNS Drugs;2024-03